GlaxoSmithKline to trim workforce at antibiotics plant in Scotland

GSK is trimming jobs at its Irvine antibiotics facility in Scotland.

GlaxoSmithKline said it is cutting an undisclosed number of jobs at its Irvine plant in North Ayrshire, Scotland.

Employees were told last week. According to the Herald, 55 positions will be eliminated; however, 11 new jobs that will be created under a new organization will offset the overall loss of headcount.

The facility, which was opened in 1973, produces antibiotics such as Augmentin. Construction to expand the facility began in 2013 to boost its production of antibiotics capacity to serve 100 million more patients a year. 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The company didn’t confirm how many positions are being eliminated at the plant; however, it did release a statement.

“GSK Irvine is vital to our medicines manufacturing network around the world, and will continue to remain so,” David Daley, GSK’s director of global corporate media relations, said in an email to FiercePharmaManufacturing. “Following a review of our work at the site, we are proposing to make some changes to the site which will potentially impact a small number of employees.”